5.3. pathophysiology. pathophysiology ed may vasculogenic, neurogenic, anatomical, hormonal, drug-induced and/or psychogenic (table 7) . cases, numerous pathophysiological pathways co-exist may negatively impact ef. table 7: urological conditions associated ed vasculogenicrecreational habits (i.e., cigarette smoking)lack regular physical exerciseobesitycardiovascular diseases (e.g., hypertension, coronary artery disease, peripheral vasculopathy)type 1 2 diabetes mellitus; hyperlipidaemia; metabolic syndrome; hyperhomocysteinemiamajor pelvic surgery (e.g., radical prostatectomy) radiotherapy (pelvis retroperitoneum)neurogeniccentral causesdegenerative disorders (e.g., multiple sclerosis, parkinson’s disease, multiple atrophy, etc.)spinal cord trauma diseasesstrokecentral nervous system tumoursperipheral causestype 1 2 diabetes mellituschronic renal failure, chronic liver failurepolyneuropathysurgery (major surgery pelvis/retroperitoneum) radiotherapy (pelvis retroperitoneum)surgery urethra (urethral stricture, open urethroplasty, etc.)anatomical structuralhypospadias, epispadias; micropenisphimosispeyronie’s diseasepenile cancer (other tumours external genitalia)hormonaldiabetes mellitus; metabolic syndrome (mets)hypogonadism (any type)hyperthyroidismhyper- hypocortisolism (cushing’s disease, etc.)panhypopituitarism multiple endocrine disordersmixed pathophysiological pathwayschronic systemic diseases (e.g., diabetes mellitus, hypertension, mets, chronic kidney disease, chronic liver disorders, hyperhomocysteinemia, hyperuricemia, chronic obstructive pulmonary disease, rheumatic disease)psoriasis, gouty arthritis, ankylosing spondylitis, non-alcoholic fatty liver disease, chronic periodontitis, open-angle glaucoma, inflammatory bowel disease, chronic fatigue syndrome, allergic rhinitis, obstructive sleep apnoea, depressioniatrogenic causes (e.g. trus-guided prostate biopsy)drug-inducedantihypertensives (i.e., thiazidediuretics, beta-blockers)*antidepressants (e.g., selective serotonin reuptake inhibitors, tricyclics)antipsychoticsantiandrogens (gnrh analogues antagonists; 5-aris)recreational drugs (e.g., heroin, cocaine, marijuana, methadone, synthetic drugs, anabolic steroids, excessive alcohol intake)psychogenicgeneralised type (e.g., lack arousal disorders sexual intimacy)situational type (e.g., partner-related, performance-related issues due distress)traumapenile fracturepelvic fracture gnrh = gonadotropin-releasing hormone; 5-aris = 5α-reductase inhibitors.*a symmetry analysis showed cardiovascular drugs strongly affect risk subsequently prescribed anti-erectogenic drug. analysis assessed short-term risk . 5.3.1. pelvic surgery prostate cancer treatment pelvic surgery, especially oncological disease (e.g., radical prostatectomy (rp) , radical cystectomy colorectal surgery ), may negative impact ef overall sexual health. surgery resulting damage neurovascular bundles, control complex mechanism cavernous erectile response, may result ed, although ns approaches adopted last decades. date surgical treatment pca enough scientific evidence supporting potential pathophysiological association ed [287-289]. however, even non-surgical treatments pca (i.e., radiotherapy, brachytherapy) associated ed . protect trial randomised 1,643 patients active treatment (rp rt) active monitoring localised pca assessed sexual function, including ef, using epic-26 instrument . baseline, 67% men reported erections firm enough sexual intercourse. six year follow-up assessment fell 30% active monitoring group, 27%% rt group 17% rp group, respectively. radical prostatectomy treatment clinically localised intermediate- high-risk pca widely performed procedure. research shown 25-75% men experience post-rp ed . conversely, rate unassisted post-operative ef recovery ranges 20 25% studies. rates substantially improved changed past seventeen years, despite growing attention post-surgical rehabilitation protocols refinement surgical techniques . overall, patient age, baseline ef surgical volume, subsequent ability preserve neurovascular bundles, main factors promoting highest rates post-operative ef . regardless surgical technique, surgeons’ experience clearly impacts post-operative ef outcome . surgical approach may also affect post-rp ef, current evidence conflicts one systematic review reporting significant advantage favour rarp compared open retropubic rp twelve-month potency rates two rcts reporting small improvement ef rarp different ef techniques . erectile dysfunction also common problem external beam radiation therapy (ebrt) brachytherapy pca. systematic review meta-analysis including men treated ebrt (65%), brachytherapy (31%) (4%) showed post-treatment prevalence ed 34% one year 57% 5.5 years, respectively . similar findings reported stereotactic radiotherapy 26-55% previously sexually functioning patients reporting ed five years . recently modalities emerged potential therapeutic options patients clinically-localised pca, including high-intensity focused us (hifu), cryo-therapeutic ablation prostate (cryotherapy), focal padeliporfin-based vascular-targeted photodynamic therapy focal rt brachytherapy cyberknife®. approaches reported less-negative impact ef many studies reporting complete recovery one-year follow-up . 5.3.2. summary evidence epidemiology/aetiology/pathophysiology ed summary evidenceleerectile dysfunction common worldwide.2berectile dysfunction shares common risk factors cardiovascular disease.2blifestyle modification (regular exercise decrease bmi) improve erectile function.1berectile dysfunction symptom, disease. patients may properly evaluated receive treatment underlying disease condition may causing ed.4erectile dysfunction common rp, irrespective surgical technique used.2berectile dysfunction common external radiotherapy brachytherapy.2berectile dysfunction less common cryotherapy high-intensity focused us.2b